Gender difference in susceptibility to smoking in Korean lung cancer patients having smoking habits

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17158-17158
Author(s):  
J. Ryu ◽  
H. Lee ◽  
J. Cho ◽  
S. Kwak ◽  
H. Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Forced Expiratory Volume ◽  
Smoking Habits ◽  
Carcinogenic Effect ◽  
Lung Cancer Patients ◽  
Susceptibility To Smoking

17158 Background: There were some controversies whether women were more or less susceptible to the carcinogenic effect of cigarette smoke and the decline of forced expiratory volume in 1 second (FEV1) to pack-years compared to men. Methods: In this study, we included all lung cancer patients having smoking habits who was histologically diagnosed and performed pulmonary function testing at the time of diagnosis from September 2001 through December 2005. We estimated individual susceptibility to smoking using a formula (SI, susceptibility index) of (100% predicted FEV1)/pack-years. Results: Of 858 lung cancer patients, sex ratio (M/F) was 14.6 (803/55). Past smokers were in 236 (29.3%) for men, 11 (20.0%) for women. Most common hsitologic type was squamous cell carcinoma (477), adenocarcinoma (191), small cell carcinoma (147), adenosquamous cell carcinoma (14), large cell carcinoma (14), NSCLC cell type not specified (15). Pack-years were 41.3 ± 18.9 for men, 29.2 ± 20.4 for women (P = 0.000). FEV1 % was 78.7 ± 23.3 for men, 79.4 ± 22.9 for women (P = 0.832). As for SI, there were no differences between men (0.65 ± 1.1) and women (0.72 ± 1.6) (P = 0.688). Conclusions: Although lung cancer women having smoking habits showed lower pack-years, there were no gender differences in terms of FEV1 decline to cigarette smoking. No significant financial relationships to disclose.

scholarly journals Bacteriological and Cytological study For bronchial washes from lung cancer patients

2011 ◽  
Vol 8 (1) ◽  
pp. 406-415
Author(s):  
Baghdad Science Journal
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Cytological Study ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Biochemical Tests ◽  
Dominant Type ◽  
Lung Cancer Patients ◽  
Esherichia Coli ◽  
Bronchial Wash

The study included the collection of 75 bronchial wash samples from patients suspected to have lung cancer. These samples were subjected to a diagnostic cytological study to detect the dominant type of lung cancer. It was noticed that 33 patients proved to have a lung cancer out of 75 (44%) of these, 19 cases (57.6%)were diagnosed having Squamus cell carcinoma,7cases (21.21%) showed Adenocarcinoma ,6 cases (18.18%) were having small cell carcinoma while only one case (3.03%)was large cell carcinoma .Nearly 70% of cases were correlated with smokers .Bacteria were isolated from 53 patients in which 33 isolates were associated with the cancer cases while 20 of them from non infected patients. By using different morphological ,biochemical tests followed by api20 ,the bacterial isolates correlated with cancer were diagnosed and were characterized as 12 isolates (36.36%) of Pseudomonas aeruginosa ,6 isolates (18.18%) were Klebsiella pneumoniae ,Pseudomonas fluorescence and Esherichia coli for each while only 3 isolates (9.09%)of Acinetobacter baumannii were isolated. Some of bacterial virulence factors were determined in which,24 isolates (72.7%) were capable of agglutinating red blood cells, 16 isolates (48.5%) had the ability to adhere to epithelial cells , in addition ,15 isolates (45.5%) proved to have capsule and 24 isolates(72.7%) gave a positive results in heamolysin test beside ,25 isolates (75.8%) were ß –Lactamase producers. The isolates were highly resisted Ampicillin, Amoxicillin and Cefotaxime while they were inhibited by low concentrations of Ciprofloxacin and Cefepime the 4th generation cephalosporins.

Comparison of Face-to-Face Interview Questionnaires and Medical Records Data for Smoking Habits in Lung Cancer Patients

2007 ◽  
Vol 62 (1) ◽  
pp. 27 ◽  
Author(s):  
Eui-Cheol Lee ◽  
Jeong-Seon Ryu ◽  
Hyun-Jung Kim ◽  
Jae-Hwa Cho ◽  
Seoung-Min Kwak ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Medical Records ◽  
Smoking Habits ◽  
Lung Cancer Patients ◽  
Face To Face

The Incidence and Outcome of Venous Thrombo-Embolism (VTE) In Non-Small Cell Lung Cancer Patients with Adenocarcinoma Histology In Comparison with Squamous Histology

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4221-4221 ◽  
Author(s):  
Ashwini Bhat ◽  
Rakesh Surapaneni ◽  
Alexandre Hageboutros ◽  
Barry Milcarek ◽  
Krystal Hunter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Abstract Abstract 4221 Background: There have been only limited studies on the incidence and outcome of venous thrombosis in non-small cell lung cancer patients by histology. Patients with adenocarcinoma are believed to have the highest risk of developing venous thrombosis. Objectives: 1. To study the incidence and outcome of thrombosis in patients with non- small cell lung cancer. 2. To determine the differences in the venous thrombotic risk between adenocarcinoma and squamous cell carcinoma subtypes. Patients/Methods: we conducted a retrospective chart review analysis of all the non-small cell lung cancer patients diagnosed in 2008 and 2009 at our institution. Patient and tumor characteristics as well as all venous thrombotic events (VTE) in the course of the disease were recorded. Incidence rates of VTE were calculated as both cumulative incidence and as person-time events (events per 1000 patient years of follow-up). We counted person-years of follow-up for each subject from the date of initial lung cancer diagnosis until the date of a thrombotic event, the date of death, or the end of the study period (30 June 2010), whichever occurred first. Analysis of the difference between squamous cell carcinoma and adenocarcinoma histological subgroups was done using Cox proportional Hazards model. For survival and outcome analysis of patients who develop VTE after diagnosis of lung cancer, we again used a Cox proportional Hazards model with the thrombotic event as a time -dependent variable. Results: Among133 patients with non-small cell lung cancer, 86 had adenocarcinoma, 42 had squamous cell histology and 5 were large cell carcinomas (the latter were excluded from the analysis). The mean age of the patients was 66.2 years and their median survival was 377 days (1.04 years).We observed 25 events of VTE over 82.89 years of follow-up for an overall incidence of VTE of 301.6 per 1000 person-years. Among 86 patients with adenocarcinoma histology, we found 21 VTEs (24.4%) Among 42 patients with squamous cell carcinoma, 4 VTE s occurred (9.5 %). The incidence of VTE for patients with adenocarcinoma was 422 per 1000 person-years (95% CI: 282 – 568) and for patients with squamous cell carcinoma 125.97 per 1000 person-years (95 % CI: 36 – 298) resulting in a trend towards higher VTE incidence in patients with adenocarcinoma as compared to patients with squamous cell carcinoma. When the rate ratio between the adenocarcinoma (21/49.7) and squamous cell cancer (4/31.8) are compared, the rate ratio is 3.359 (1.207 – 9.352). The risk of developing a VTE was 2 fold increased for patients with adenocarcinoma vs. squamous cell carcinoma (crude hazard ratio 2.375 [95%CI: 0.664–8.491]) There was a trend towards lower survival time in patients who develop a VTE during the course of their disease compared to patients who did not develop a VTE. (HR 0.992, 95% CI:.449 – 2.193). 5 of the 21 patients in the adenocarcinoma group who had VTE had a second VTE despite anticoagulation. Discussion: Only few studies have described the absolute risk as incidence rates of VTE in lung cancer patients. One study in 2004 reported the incidence of VTE is 20-fold increased in lung cancer patients compared to general population; with 3-fold increase in patients with adenocarcinoma histology. Our study confirms the trend towards increased risk of VTE in adenocarcinoma histology, along with a worse outcome. Also, of interest, is the unusually high incidence of VTE noted in our study cohort compared to the reference studies (20.9% vs. 7.2%). This finding might be due to the enhanced awareness and high clinical suspicion leading to increased testing for VTE in the cancer patients. Based on these findings, prophylactic anticoagulation in these patients may be warranted to prevent development of venous thrombosis. This needs to be studied in a prospective clinical trial in the future. Disclosures: No relevant conflicts of interest to declare.

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

1985 ◽  
Vol 3 (11) ◽  
pp. 1478-1485 ◽  
Author(s):  
D Osoba ◽  
J J Rusthoven ◽  
K A Turnbull ◽  
W K Evans ◽  
F A Shepherd
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Entire Group ◽  
Small Cell Lung

Fifty-three patients with recurrent and advanced stage (III and IV) non-small-cell lung cancer (NSCLC) were treated with a combination of bleomycin, etoposide (VP-16-213), and cis-diamminedichloroplatinum (BEP). Forty-eight patients were appraisable for response. The response rates were 44% for the entire group, 57% in 30 patients with combined squamous-cell and large-cell carcinoma, and 22% in 18 patients with adenocarcinoma (40%, 50%, and 19%, respectively, if patients not appraisable for response are included as nonresponders). The median survival time of patients with squamous-cell and large-cell carcinoma was slightly longer than that of patients with adenocarcinoma (23 weeks v 19 weeks). Patients with responsive disease survived significantly longer (median, 34 weeks) than did patients with unresponsive disease (median, 16 weeks) (P = .001). In the entire group, the median survival time of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was better (23 weeks) than of those with a status of 2 or 3 (15 weeks), but this difference was not seen in the subgroup with squamous-cell and large-cell carcinoma (24 weeks v 23 weeks, respectively). Thus, the performance status was not of prognostic value in the histologic subgroups experiencing the best response rate. There were two treatment-related deaths, but otherwise the toxicity of BEP was acceptable. Only four of the 119 treatment cycles were followed by fever even though there was significant neutropenia (0.5 X 10(9)/L) after 20 of 97 treatment cycles. The majority of patients receiving BEP experienced relief of cough, hemoptysis, pain, and fatigue associated with their disease. There was a good correlation between objective responses and palliation of symptoms. Thus, BEP offers good palliation, particularly for patients with squamous-cell and large-cell lung cancer.

Sign in / Sign up

Export Citation Format

Share Document